Advertisement
Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientistin its Strategic Consulting Services (SCS) group, based in Europe. Dr. Lindbomjoins Pharsight from Uppsala University's department of PharmaceuticalBiosciences in Sweden, where he held a postdoctoral research fellowshipsponsored by Pfizer. He also served as a bioinformatics software systemsdeveloper within the discovery research organization at AstraZeneca. Dr.Lindbom has broad experience with population pharmacokinetic andpharmacodynamic (PK/PD) modeling and pharmacometric method development, withan emphasis in computer-intensive statistical methods.
Advertisement
Dr. Lindbom holds a Ph.D. from Uppsala University's department ofPharmaceutical Biosciences, within the National Network in Drug Development,Swedish Foundation for Strategic Research. Dr. Lindbom has authored or co-authored several original research articles in the field ofpharmacostatistical modeling and has given invited presentations on Perl-speaks-NONMEM (PsN), a collection of computer programs aiding in thedevelopment of non-linear mixed effects models using NONMEM, to which he was adeveloper and remains an active contributor.
Pharsight's recently launched Reporting and Analysis Services (RAS)business unit has added a PK scientist in response to increased global demandfor the group's PK/PD analysis and reporting services. The RAS team has alsoadded a Quality Assurance Inspector to support delivery of high quality,regulatory-compliant clinical study analyses and reports for new drug approval.Since its launch in May 2007, the RAS unit has more than tripled its staff andhas plans to expand its facilities in Montreal, Canada. In addition, the RASunit has accepted into its internship program a student working towards a Ph.D.in Pharmaceutical Sciences at the University of Montreal.
"The addition of new expert staff in both the SCS and RAS business unitswill further enhance our ability to address the full spectrum of client needsin modeling and simulation," said Shawn O'Connor, president, chief executiveofficer and chairman of Pharsight. "Lars brings to SCS a wealth of expertisein the area of PK/PD modeling and advanced statistical methods. The additionof yet another talented, highly experienced scientist in the SCS group willhelp us meet the growing demand for applying model-based drug developmentapproaches to support our client's decision-making processes."
"In addition to the expansion of the SCS team, we have continued to growour RAS group's capabilities by bringing on new talent," continued Mr.O'Connor. "Requirements for regulatory-compliant analysis and reporting ofPK/PD data to support new drug submissions has driven new customer demand forour RAS offering. We are pleased to extend Pharsight's internship program tocover our entire consulting services practice, which provides talented Ph.D.students with opportunities to work on projects and gain in-depth modeling andsimulation expertise. We look forward to contributions from our newestcolleagues that will further enhance the services that we provide to ourclients."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products andservices that enable pharmaceutical and biotechnology companies to achievesignificant and enduring improvements in the development and use oftherapeutic products. Pharsight's goal is to help customers reduce the time
